CAMBRIDGE, Mass. - Decoy Therapeutics Inc. (NASDAQ:DCOY) announced today the nomination of Patricia Gauthier as a Class II director, according to a press release statement. Shareholders will vote on the nomination at the company’s annual meeting on July 14, 2026.
Gauthier serves as Senior Vice President and Regional Head for Australia, Canada and the United Kingdom at Moderna, a position she has held since 2025. In this role, she oversees strategy and operations across biomanufacturing, national health security partnerships and commercialization for approximately 500 employees.
Before her current position, Gauthier was General Manager of Moderna Canada, where she established the affiliate and supported the delivery of more than 50 million COVID-19 vaccine doses. She also participated in securing a biomanufacturing partnership with the Government of Canada. Prior to Moderna, she held senior leadership positions at GSK in vaccines, specialty care, market access and government affairs. She began her career as a lawyer at McCarthy Tétrault.
The nomination follows the completion of David Arthur’s service on the board. Arthur previously contributed to Salarius Pharmaceuticals, Decoy’s predecessor company.
"Patricia has spent her career making sure important medicines reach the people who need them, at scale and in the real world," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics.Gauthier joins the board at a pivotal time for the company, which currently trades at $8.61 with a market capitalization of $4.58 million. The stock has shown recent momentum with an 11% gain year-to-date, though it remains down 94% over the past year. According to InvestingPro analysis, the company appears undervalued at current levels, with analysts setting a price target of $30.
Decoy Therapeutics develops what it describes as Designable Multi-Antivirals, which the company states are engineered to target shared viral mechanisms. The company’s lead candidates target multiple respiratory viruses.
In other recent news, Decoy Therapeutics has outlined key milestones for its antiviral pipeline, including collaborations with Quantori and Google Cloud to enhance computational peptide design capabilities. The company also announced its selection as a Hello Tomorrow Deep Tech Pioneer and a global access commitment with the Gates Foundation. Decoy Therapeutics has regained compliance with Nasdaq’s minimum bid price requirement, as confirmed by Nasdaq Stock Market LLC. The company is now compliant with all applicable listing requirements for The Nasdaq Capital Market. Additionally, Decoy Therapeutics has appointed MIT Professor Brad L. Pentelute as Chair of its Scientific Advisory Board, where he will guide the scientific direction of the company’s IMP3ACT platform. The company has also set its 2026 Annual Meeting of Stockholders for July 14, with details to be provided in an upcoming proxy statement. These developments highlight Decoy Therapeutics’ ongoing efforts in scientific advancement and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for DCOY plus thousands of other stocks and find your next hidden gem with massive upside.